Expert Voices in Dementia

Practical Neurology

Thought leaders from the field present insights from dementia research, clinical practice, and caregiving that will help you maximize the quality of life and well-being of your patients

Listen in PodNod RSS feed

20 episodes
Updated July 13

Episodes20

Newest first

July 13 · 9 min
Clinician-Reported Factors Influencing Cognitive Evaluations in Primary Care
Kyra O'Brien, MD, Assistant Professor of Neurology at the Hospital of the University of Pennsylvania discusses modifiable barriers to performing cognitive evaluations in primary care based on the results of the study, Clinician-reported Factors Influencing Performance of Cognitive Evaluations in Primary Care. Learn more about your ad choices. Visit megaphone.fm/adchoices
Oct 9, 2025 · 11 min
Key Takeaways from AAIC 2025: Lifestyle Modifications, Biomarkers, Amyloid-Targeting Therapies, and More
Ana C. Pereira, MD, Associate Professor, Icahn School of Medicine at Mount Sinai, New York, NY, discusses key takeaways about the impact of patient lifestyle modifications on brain health, updates in biomarkers and disease-modifying therapies, and new frontiers in Alzheimer disease research based on research presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC). Learn more about your ad choices. Visit megaphone.fm/adchoices
Oct 8, 2025 · 14 min
The Brain Health Navigator: A Novel Program to Improve Alzheimer Disease Care
Gregory E. Cooper, MD, PhD, Director, Memory Center, Norton Neuroscience Institute, Louisville, KY, outlines the Brain Health Navigator program as a strategy to streamline dementia care pathways, ensuring earlier diagnosis and faster access to disease-modifying therapies. This program, developed by the Davos Alzheimer’s Collaborative, is designed to reduce system inefficiencies across primary and specialty care and improve access for all patients. Learn more about your ad choices. Visit megaphone.fm/adchoices
Sep 9, 2025 · 21 min
Beyond Slowing Cognitive Decline: Patient and Caregiver Perspectives on Alzheimer’s Treatment
This episode explores groundbreaking qualitative research from the University of Pennsylvania on patient and caregiver perspectives in Alzheimer disease. Dr. Katie Auriemma, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, and Dr. Carolyn Chow, Penn Medicine, Philadelphia, PA, discuss findings from interviews with patients and caregivers that reveal hopes, worries, and nuanced views on AD therapies—highlighting the importance of patient-centered outcomes, shared decision-making, and aligning treatment with family goals. Learn more about your ad choices. Visit megaphone.fm/adchoices
May 1, 2025 · 17 min
Beyond the Boardroom: Barbara Corcoran on Caregiving and Alzheimer Disease
In this episode, we are joined by entrepreneur and television personality, Barbara Corcoran. While many know Barbara for her business acumen and dynamic presence on Shark Tank, fewer may know the deeply personal and powerful story she shares today—her nine-year journey as a caregiver for her mother, who lived with Alzheimer disease. In this heartfelt conversation, Barbara opens up about the early signs her family overlooked, the emotional toll of watching her mother's personality shift, and the pivotal moment that changed their approach to caregiving. From practical strategies to navigate agitation in Alzheimer disease, to profound lessons in empathy, patience, and family dynamics, Barbara’s story offers inspiration and wisdom for caregivers and physicians. For more information, please visit www.RecognizeAlzheimersAgitation.com. Learn more about your ad choices. Visit megaphone.fm/adchoices
Mar 21, 2025 · 20 min
Plasma P-Tau217: Detecting Alzheimer Disease with a Blood Test
Sterling Johnson, PhD, Associate Director and Biomarker Core Leader in the Wisconsin Alzheimer’s Disease Research Center (ADRC), and a Clinical Neuropsychologist and Neuroscientist focused on understanding AD-related changes in the brain, details his research into the use of plasma p-tau217 as a blood-based biomarker for detecting Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
Feb 25, 2025 · 11 min
Updated Criteria for Diagnosis and Staging of Alzheimer Disease: Recommendations of the International Working Group
Nicolas Villain, MD, PhD, Associate Professor of Neurology, Sorbonne University, Paris, France, discusses the International Working Group’s updated diagnostic criteria for the diagnosis and staging of Alzheimer disease, which offer an alternative definitional view of AD as a clinical-biologic construct. Learn more about your ad choices. Visit megaphone.fm/adchoices
Jan 25, 2025 · 16 min
Blarcamesine: An Investigational Oral Drug for Alzheimer Disease
Timo Grimmer, MD, Associate Professor of Psychiatry and Psychotherapy and Head of the Centre for Cognitive Disorders at the Technical University of Munich, Germany, discusses the experimental oral small molecule drug blarcamesine, which is under investigation as a potential treatment for Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
Dec 19, 2024 · 10 min
The CMS GUIDE Model To Support Patients with Dementia and Their Caregivers
Sarena Ho, Health Insurance Specialist at the CMS Innovation Center, provides an overview on the Guiding an Improved Dementia Experience (GUIDE) Model, which helps physicians provide coordinated care to support patients with dementia and their caregivers. Learn more about your ad choices. Visit megaphone.fm/adchoices
Nov 19, 2024 · 15 min
The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease
Gary E. Gibson, PhD, Professor of Neurosciences, Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, details his research related to metabolic changes associated with Alzheimer disease and a clinical trial studying the effects of benfotiamine therapy on cognitive and other outcomes. Learn more about your ad choices. Visit megaphone.fm/adchoices
Nov 8, 2024 · 7 min
BrainCheck as a Digital Cognitive Assessment Tool
Kim Rodriguez, CEO of BrainCheck, provides an overview of the company's cognitive assessment plan and how clinicians can use these tools in practice. Learn more about your ad choices. Visit megaphone.fm/adchoices
Sep 27, 2024 · 12 min
Kramer, Van Dyck
Lynn D. Kramer, MD, FAAN, Chief Clinical Officer, Deep Human Biology Learning at Eisai and a member of the Eisai Executive Committee, and Christopher van Dyck, MD, Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, provide an overview of key results from the Clarity AD clinical trial assessing the safety and efficacy of lecanemab in people with early Alzheimer disease presented at the 2024 Alzheimer's Association International Conference. Learn more about your ad choices. Visit megaphone.fm/adchoices
Sep 21, 2024 · 10 min
CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3
In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this episode, Dr. Schindler provides advice for physicians about communicating biomarker test results with their patients. Learn more about your ad choices. Visit megaphone.fm/adchoices
Sep 21, 2024 · 17 min
CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2
In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this episode, Dr. Schindler presents an overview of factors influencing the selection of cerebrospinal fluid, PET, and blood-based biomarker tests. Learn more about your ad choices. Visit megaphone.fm/adchoices
Sep 21, 2024 · 8 min
CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1
In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this episode, Dr. Schindler discusses key factors physicians should consider when ordering a biomarker test and recommendations for how physicians should communicate the need for a particular test with their patients. Learn more about your ad choices. Visit megaphone.fm/adchoices
Sep 16, 2024 · 12 min
Labcorp's Biomarker Testing for Alzheimer Disease
Joseph M. Volpe, MD, Discipline Director, Clinical Neuroscience, Labcorp, discusses biomarker testing for Alzheimer disease and dementia,, including current offerings, reimbursement, and future directions in this evolving area. Learn more about your ad choices. Visit megaphone.fm/adchoices
Jul 19, 2024 · 20 min
What Neurologists Should Know About End-of-Life Care Discussions
Dan Morhaim, MD, board-certified emergency medicine and internal medicine physician, and former 24-year Maryland State Legislator, highlights the importance of discussing end-of-life care issues with dementia patients and best practices for physicians to follow when broaching this topic. Learn more about your ad choices. Visit megaphone.fm/adchoices
Jul 15, 2024 · 22 min
Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders
Virginia Man-Yee Lee, PhD, who serves as the John H. Ware 3rd Endowed Professor in Alzheimer's Research at the University of Pennsylvania Perelman School of Medicine, the Director of the Center for Neurodegenerative Disease Research, and Co-Director of the Marian S. Ware Center for Alzheimer's Drug Discovery, presents an overview of tau biomarker testing and research. Learn more about your ad choices. Visit megaphone.fm/adchoices
Jul 15, 2024 · 9 min
Strategies to Limit ARIA Associated with Alzheimer Disease Treatment
Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab. Learn more about your ad choices. Visit megaphone.fm/adchoices
Jul 15, 2024 · 8 min
Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab
Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss recent data analyzing the real-world implications of donanemab treatment for people with Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

Expert Voices in Dementia

Clinician-Reported Factors Influencing Cognitive Evaluations in Primary Care

Key Takeaways from AAIC 2025: Lifestyle Modifications, Biomarkers, Amyloid-Targeting Therapies, and More

The Brain Health Navigator: A Novel Program to Improve Alzheimer Disease Care

Beyond Slowing Cognitive Decline: Patient and Caregiver Perspectives on Alzheimer’s Treatment

Beyond the Boardroom: Barbara Corcoran on Caregiving and Alzheimer Disease

Plasma P-Tau217: Detecting Alzheimer Disease with a Blood Test

Updated Criteria for Diagnosis and Staging of Alzheimer Disease: Recommendations of the International Working Group

Blarcamesine: An Investigational Oral Drug for Alzheimer Disease

The CMS GUIDE Model To Support Patients with Dementia and Their Caregivers

The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease

BrainCheck as a Digital Cognitive Assessment Tool

Kramer, Van Dyck

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1

Labcorp's Biomarker Testing for Alzheimer Disease

What Neurologists Should Know About End-of-Life Care Discussions

Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab